Percutaneous transluminal renal angioplasty in children and adolescents.

Mali, W. P. T. M.; Puijlaert, C. B. A. J.; Kouwenberg, H J; Klinge, J.; Donckerwolcke, R A; Geijskes, B G; Overbosch, E. H.; Rosenbusch, Gerd; Ludwig, Wesley W.; Feldberg, M. A. M.

doi:10.1148/radiology.165.2.2958896

Cited by 44 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tyagi et al (17) found that patients with discrete stenosis (≤10 mm) or residual stenosis (≤20%) had a better blood pressure response. Similar results were also reported in another study (18). Supporting the notion that stenosis length is the main determinant of clinical success with PTRA (19), we found that the length of stenosis was significantly shorter in patients who were cured or improved after PTRA treatment than in those who failed to respond to the treatment (8.06±3.10 mm vs. 16.6±5.16 mm, P < 0.01), and our logistic regression analysis showed that the length of stenosis was inversely correlated with the effectiveness rate of PTRA.…”

Section: Discussionsupporting

confidence: 93%

Angioplasty for pediatric renovascular hypertension: a 13-year experience

Zhu

He²,

Gu³

et al. 2014

Diagn Interv Radiol

View full text Add to dashboard Cite

ORIGINAL ARTICLE PURPOSE We aimed to evaluate the long-term outcome and efficacy of percutaneous transluminal renal angioplasty (PTRA) for pediatric renal artery stenosis (RAS), which is an important cause of medication-refractory pediatric hypertension. MATERIALS AND METHODSWe retrospectively evaluated 22 hypertensive children (age range, 3-17 years) who underwent PTRA from February 2000 to July 2012. Sixteen patients had Takayasu arteritis and six fibromuscular dysplasia. Five were not included in the statistical analysis due to loss to follow-up. RESULTSTechnical success was achieved in 32 of 34 procedures (94.1%). The stenosis rate decreased from 84.5% before PTRA to 20.1% after PTRA. Treatment was effective in 72.7% (16/22) of patients, including complete cure in 27.3% (6/22) and improvement in 45.5% (10/22). Systolic and diastolic blood pressures decreased from 153±19.1 to 131.7±21.4 mmHg and from 97.9±14.2 to 83.6±19.3 mmHg, respectively (P < 0.01). Number of antihypertensive agents decreased from 2.7 to 0.5 per patient. Restenosis was detected in 40.9% (9/22) of patients, with a restenotic interval of 11.8 months (range, 3-47 months). Lesion length was strongly correlated with clinical success (cure and improvement) (independent-sample t test, P < 0.001; binary logistic regression, P = 0.040). CONCLUSIONLesion length is an important determination of clinical success with PTRA for pediatric RAS. PTRA is an appropriate treatment option for pediatric renovascular hypertension due to Takayasu arteritis and fibromuscular dysplasia.

show abstract

Section: Discussionsupporting

confidence: 93%

Angioplasty for pediatric renovascular hypertension: a 13-year experience

Zhu

He²,

Gu³

et al. 2014

Diagn Interv Radiol

View full text Add to dashboard Cite

show abstract

“…In addition to medical management, RAS has been traditionally treated with vascular surgery. After the first successful renal artery angioplasty of a child in 1980 [11], there has been growing experience with PTRA in children with RAS during the past several years [12][13][14][15][16][17][18][19]. The success rate of PTRA in children with RAS varies from 25 to 94%.…”

Section: Discussionmentioning

confidence: 99%

Mid-aortic syndrome: A case report and review of the literature

Lin

Hwang

Lee

et al. 2008

International Journal of Cardiology

View full text Add to dashboard Cite

“…57 A strong association among NF-1, abdominal aortic coarctation, 1-12,14,16-18,24,52-56 and/or renal ostial stenosis has been reported. [1][2][3][4][5][7][8][9][10][11][13][14][15][16][17][18]24,[37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53] Stenoses/aneurysms have been identified also in the visceral, 10,16-19,24,61,71-73 coronary, 23,57 and cerebrovascular circulations 10,28,32,33,[58][59][60] in addition to the thoracic aorta and the subclavian and innominate arteries (see Table 2). 9,25,28,56,…”

Section: Vascular Abnormalitiesmentioning

confidence: 99%

Neurofibromatosis Type 1: From Presentation and Diagnosis to Vascular and Endovascular Therapy

Delis

Gloviczki²

2006

Perspectives in Vascular Surgery and Endovascular Therapy

View full text Add to dashboard Cite

Neurofibromatosis type 1, also called von Recklinghausen's disease, is an autosomal dominant disorder linked to chromosome 17, characterized by growth impairment of the neural crest cells (ectoderm) manifested by multiple neural tumors, cutaneous pigmentations, and Lisch nodules. Disease phenotype develops with time, making its penetrance almost complete by 5 years of age. Compression of the gastro-intestinal, urinary, or pulmonary tracts by visceral neurofibromas may generate serious complications. Neurofibromatosis type 1 is remarkable for its association with occlusive (stenoses) or aneurysmal arterial disease affecting predominantly the renal arteries and less often the abdominal aorta (middle aortic syndrome), and mesenteric and peripheral arteries. Appraisal of existing literature reveals that timely vascular intervention by way of conventional surgery and/or endovascular therapy may provide patients with effective and durable treatment. The far greater propensity for malignant connective/soft-tissue neoplasms and vascular disease in neurofibromatosis type 1, amid potential complications from the gastro-intestinal, urinary, and pulmonary tracts, leads to a significantly increased morbidity and decreased life expectancy. Neurofibromatosis type 1, from presentation and diagnosis to its treatment, is reviewed, with emphasis on vascular disease and its management with open vascular surgery and endovascular therapy.

show abstract

Percutaneous transluminal renal angioplasty in children and adolescents.

Cited by 44 publications

References 0 publications

Angioplasty for pediatric renovascular hypertension: a 13-year experience

Angioplasty for pediatric renovascular hypertension: a 13-year experience

Mid-aortic syndrome: A case report and review of the literature

Neurofibromatosis Type 1: From Presentation and Diagnosis to Vascular and Endovascular Therapy

Contact Info

Product

Resources

About